Sign in
4

Changes in Ownership

Oruka Therapeutics, Inc. Filed Acc 0000907654-26-000069

Chief Operating Officer sold 5,000 shares at an average $94.42 ($472,079)

  • Chief Operating Officer acquired 5,000 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Sandler Laura Lee · Chief Operating Officer

Table I: Non-derivative

4 lines
Date Transaction Shares Price Value Owned after D/I
2026-07-01 Exercise or conversion : show line 1 in the form 10b5-1 +5,000 $7.80 $39,000 241,384 D
2026-07-01 Sale : show line 2 in the form 10b5-1 −2,237 $93.85 $209,933 239,147 D
2026-07-01 Sale : show line 3 in the form 10b5-1 −2,263 $94.75 $214,410 236,884 D
2026-07-01 Sale : show line 4 in the form 10b5-1 −500 $95.47 $47,736 236,384 D
Open-market sales · 5,000 sh · avg $94.42 · $472,079

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2026-07-01 Exercise or conversion : show line 5 in the form 10b5-1 Employee Warrant (right to buy) −5,000 79,996 D
Loading xslF345X06/form4.xml…